B

Blueprint Medicines Corp
D

BPMC

90.120
USD
1.13
(1.27%)
Market Closed
Volume
26,798
EPS
-4
Div Yield
-
P/E
-43
Market Cap
5,724,948,521
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    4.190
    (2.44%)
    175.700 USD
    AMGN
    AMGN
    2.27
    (0.87%)
    263.46 USD
    BMY
    BMY
    0.990
    (1.76%)
    57.280 USD
    GILD
    GILD
    1.460
    (1.60%)
    92.570 USD
    GSK
    GSK
    0.155
    (0.46%)
    33.595 USD
    JNJ
    JNJ
    0.890
    (0.62%)
    144.450 USD
    LLY
    LLY
    11.01
    (1.45%)
    768.44 USD
    MRK
    MRK
    -1.390
    (-1.40%)
    98.150 USD
    PFE
    PFE
    0.595
    (2.31%)
    26.360 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    VRTX
    VRTX
    0.58
    (0.15%)
    397.15 USD
    More
News

Title: Blueprint Medicines Corp

Sector: Healthcare
Industry: Biotechnology
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.